Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) shares traded down 0.9% during trading on Tuesday . The company traded as low as $53.81 and last traded at $53.94, with a volume of 143,064 shares. The stock had previously closed at $54.45.

A number of research analysts have commented on the stock. Goldman Sachs Group Inc. assumed coverage on shares of Dr. Reddy’s Laboratories in a research note on Monday, May 2nd. They set a “neutral” rating for the company. Zacks Investment Research upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research note on Tuesday, April 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Dr. Reddy’s Laboratories presently has a consensus rating of “Hold” and an average target price of $61.00.

The company has a 50-day moving average price of $48.03 and a 200 day moving average price of $45.71. The firm has a market capitalization of $9.19 billion and a PE ratio of 31.09.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings data on Thursday, May 12th. The company reported $0.07 earnings per share for the quarter. The firm had revenue of $567 billion for the quarter, compared to analyst estimates of $2.41 billion. On average, equities analysts expect that Dr. Reddy’s Laboratories Ltd. will post $2.05 EPS for the current year.

The company also recently disclosed an annual dividend, which will be paid on Monday, July 18th. Stockholders of record on Monday, July 18th will be paid a dividend of $0.277 per share. The ex-dividend date is Thursday, July 14th.

Other hedge funds and institutional investors have recently added to or reduced their stakes in the company. OppenheimerFunds Inc. raised its position in Dr. Reddy’s Laboratories by 10.5% in the fourth quarter. OppenheimerFunds Inc. now owns 37,908 shares of the company’s stock valued at $1,755,000 after buying an additional 3,600 shares in the last quarter. Advisors Asset Management Inc. raised its position in Dr. Reddy’s Laboratories by 3.2% in the fourth quarter. Advisors Asset Management Inc. now owns 43,693 shares of the company’s stock valued at $2,023,000 after buying an additional 1,341 shares in the last quarter. GAM Holding AG raised its position in Dr. Reddy’s Laboratories by 157.7% in the fourth quarter. GAM Holding AG now owns 123,200 shares of the company’s stock valued at $5,703,000 after buying an additional 75,400 shares in the last quarter. Russell Frank Co raised its position in Dr. Reddy’s Laboratories by 8.6% in the fourth quarter. Russell Frank Co now owns 161,832 shares of the company’s stock valued at $7,492,000 after buying an additional 12,758 shares in the last quarter. Finally, Morgan Stanley raised its position in Dr. Reddy’s Laboratories by 366.0% in the fourth quarter. Morgan Stanley now owns 308,997 shares of the company’s stock valued at $14,303,000 after buying an additional 242,689 shares in the last quarter.

Dr. Reddy’s Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.